共 59 条
[1]
Ciccolini J(2006)Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency Cancer Chemother Pharmacol 58 272-275
[2]
Mercier C(1999)Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage J Clin Oncol 17 1105-228
[3]
Dahan L(2010)Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer 9 224-1650
[4]
Gamelin E(2015)Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data Lancet Oncol 16 1639-234
[5]
Boisdron-Celle M(2016)Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis J Clin Oncol 34 227-517
[6]
Guérin-Meyer V(2020)Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines Eur J Hum Genet 28 508-729
[7]
Ciccolini J(2016)Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients Pharmacogenomics 17 721-1467
[8]
Gross E(2018)DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis Lancet Oncol 19 1459-2253
[9]
Dahan L(1994)Population study of dihydropyrimidine dehydrogenase in cancer patients J Clin Oncol 12 2248-239
[10]
Lacarelle B(1995)Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography J Chromatogr B, Biomed Appl 672 233-390